Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico acuto-1 - GISSI-1
Streptokinase vs. placebo for mortality in acute myocardial infarction.
To evaluate the efficacy of streptokinase for acute myocardial infarction.
Patients Screened: Not given
Patients Enrolled: 11,712
Mean Follow Up: 1 year
Acute myocardial infarction
Streptokinase, 1.5 million units IV over 1 hour, or placebo
Heparin, nitrates, calcium channel blockade, antiplatelet agents, beta blockade at investigators discretion.
There was an 18% relative reduction in 21-day mortality for patients receiving streptokinase (10.7%) compared to placebo (13%), which was highly significant (p=0.0002). At 12 months, total mortality was significantly lower for the streptokinase group (17.2% compared to 19% for the placebo group, p=0.0008).
There was a larger relative reduction in mortality for patients receiving thrombolytic therapy within 3 hours after onset of symptoms.
The GISSI study was one of the initial landmark studies that documented the large mortality benefits possible with thrombolytic therapy, and signaled the dawn of a new era for treatment of myocardial infarction.
1. Lancet 1986;I:397-402. Final results
2. Lancet 1987;II:871-4. Long-term follow-up
Keywords: Thrombolytic Therapy, Myocardial Infarction, Streptokinase
< Back to Listings